Research programme: chimeric antigen receptor T-cell therapies - FastBack Bio
Alternative Names: Research programme: CAR T-cell therapies - FastBack BioLatest Information Update: 29 Oct 2021
At a glance
- Originator FastBack Bio
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours